nodes	percent_of_prediction	percent_of_DWPC	metapath
Zonisamide—CA5B—cervicothoracic ganglion—systemic scleroderma	0.0628	0.261	CbGeAlD
Zonisamide—AOX1—Methotrexate—systemic scleroderma	0.036	0.663	CbGbCtD
Zonisamide—CA8—artery—systemic scleroderma	0.023	0.0956	CbGeAlD
Zonisamide—CA8—blood vessel—systemic scleroderma	0.0179	0.0745	CbGeAlD
Zonisamide—CYP2C19—Prednisone—systemic scleroderma	0.00876	0.161	CbGbCtD
Zonisamide—SCN3B—tendon—systemic scleroderma	0.00619	0.0258	CbGeAlD
Zonisamide—SCN1B—lung—systemic scleroderma	0.00589	0.0245	CbGeAlD
Zonisamide—CA13—digestive system—systemic scleroderma	0.00567	0.0236	CbGeAlD
Zonisamide—SCN3B—lung—systemic scleroderma	0.00543	0.0226	CbGeAlD
Zonisamide—CA13—tendon—systemic scleroderma	0.0054	0.0225	CbGeAlD
Zonisamide—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0053	0.0975	CbGbCtD
Zonisamide—SCN4B—tendon—systemic scleroderma	0.00527	0.0219	CbGeAlD
Zonisamide—CA13—lung—systemic scleroderma	0.00474	0.0197	CbGeAlD
Zonisamide—SCN4B—lung—systemic scleroderma	0.00462	0.0192	CbGeAlD
Zonisamide—CA11—tendon—systemic scleroderma	0.00453	0.0189	CbGeAlD
Zonisamide—CYP3A4—Prednisone—systemic scleroderma	0.00424	0.078	CbGbCtD
Zonisamide—CA3—connective tissue—systemic scleroderma	0.00402	0.0167	CbGeAlD
Zonisamide—CA11—lung—systemic scleroderma	0.00398	0.0165	CbGeAlD
Zonisamide—SCN11A—digestive system—systemic scleroderma	0.00388	0.0162	CbGeAlD
Zonisamide—CACNA1G—digestive system—systemic scleroderma	0.0037	0.0154	CbGeAlD
Zonisamide—CA7—digestive system—systemic scleroderma	0.00317	0.0132	CbGeAlD
Zonisamide—CACNA1H—smooth muscle tissue—systemic scleroderma	0.00307	0.0128	CbGeAlD
Zonisamide—CA12—connective tissue—systemic scleroderma	0.00285	0.0119	CbGeAlD
Zonisamide—CA9—digestive system—systemic scleroderma	0.00278	0.0116	CbGeAlD
Zonisamide—CA3—tendon—systemic scleroderma	0.00277	0.0115	CbGeAlD
Zonisamide—CA9—tendon—systemic scleroderma	0.00265	0.011	CbGeAlD
Zonisamide—CA14—tendon—systemic scleroderma	0.00251	0.0104	CbGeAlD
Zonisamide—SCN9A—tendon—systemic scleroderma	0.00246	0.0102	CbGeAlD
Zonisamide—CA3—lung—systemic scleroderma	0.00243	0.0101	CbGeAlD
Zonisamide—SCN4A—tendon—systemic scleroderma	0.0022	0.00913	CbGeAlD
Zonisamide—SCN9A—lung—systemic scleroderma	0.00216	0.00898	CbGeAlD
Zonisamide—CA12—digestive system—systemic scleroderma	0.00206	0.00856	CbGeAlD
Zonisamide—SCN1A—lung—systemic scleroderma	0.00186	0.00773	CbGeAlD
Zonisamide—MAOB—connective tissue—systemic scleroderma	0.00183	0.00762	CbGeAlD
Zonisamide—SCN5A—digestive system—systemic scleroderma	0.00179	0.00744	CbGeAlD
Zonisamide—CA5B—tendon—systemic scleroderma	0.00176	0.00731	CbGeAlD
Zonisamide—CA12—lung—systemic scleroderma	0.00172	0.00715	CbGeAlD
Zonisamide—AOX1—digestive system—systemic scleroderma	0.00172	0.00714	CbGeAlD
Zonisamide—SCN3A—tendon—systemic scleroderma	0.00171	0.0071	CbGeAlD
Zonisamide—AOX1—tendon—systemic scleroderma	0.00163	0.0068	CbGeAlD
Zonisamide—SCN3B—Direct p53 effectors—GDF15—systemic scleroderma	0.00163	0.0583	CbGpPWpGaD
Zonisamide—CA1—digestive system—systemic scleroderma	0.00163	0.00678	CbGeAlD
Zonisamide—MAOA—connective tissue—systemic scleroderma	0.00156	0.0065	CbGeAlD
Zonisamide—CA5B—lung—systemic scleroderma	0.00154	0.00641	CbGeAlD
Zonisamide—SCN3A—lung—systemic scleroderma	0.0015	0.00623	CbGeAlD
Zonisamide—CA2—connective tissue—systemic scleroderma	0.00146	0.00609	CbGeAlD
Zonisamide—AOX1—lung—systemic scleroderma	0.00143	0.00597	CbGeAlD
Zonisamide—CA1—lung—systemic scleroderma	0.00136	0.00566	CbGeAlD
Zonisamide—CA2—smooth muscle tissue—systemic scleroderma	0.00134	0.00557	CbGeAlD
Zonisamide—MAOB—digestive system—systemic scleroderma	0.00132	0.0055	CbGeAlD
Zonisamide—CA2—skin of body—systemic scleroderma	0.00132	0.0055	CbGeAlD
Zonisamide—CA4—digestive system—systemic scleroderma	0.00127	0.0053	CbGeAlD
Zonisamide—MAOB—tendon—systemic scleroderma	0.00126	0.00524	CbGeAlD
Zonisamide—CA4—tendon—systemic scleroderma	0.00121	0.00504	CbGeAlD
Zonisamide—CYP2C19—digestive system—systemic scleroderma	0.00115	0.0048	CbGeAlD
Zonisamide—MAOA—digestive system—systemic scleroderma	0.00113	0.0047	CbGeAlD
Zonisamide—MAOB—lung—systemic scleroderma	0.00111	0.0046	CbGeAlD
Zonisamide—AOX1—Effects of Nitric Oxide—NOS3—systemic scleroderma	0.0011	0.0393	CbGpPWpGaD
Zonisamide—MAOA—tendon—systemic scleroderma	0.00107	0.00447	CbGeAlD
Zonisamide—CA4—lung—systemic scleroderma	0.00106	0.00443	CbGeAlD
Zonisamide—CA2—digestive system—systemic scleroderma	0.00106	0.0044	CbGeAlD
Zonisamide—SCN3B—Direct p53 effectors—IRF5—systemic scleroderma	0.00101	0.036	CbGpPWpGaD
Zonisamide—CA2—tendon—systemic scleroderma	0.00101	0.00418	CbGeAlD
Zonisamide—MAOA—lung—systemic scleroderma	0.000943	0.00392	CbGeAlD
Zonisamide—SCN4B—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000896	0.032	CbGpPWpGaD
Zonisamide—CA2—lung—systemic scleroderma	0.000883	0.00367	CbGeAlD
Zonisamide—SCN3B—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000833	0.0297	CbGpPWpGaD
Zonisamide—MAOB—Alpha-synuclein signaling—BLK—systemic scleroderma	0.000801	0.0286	CbGpPWpGaD
Zonisamide—CYP3A4—digestive system—systemic scleroderma	0.000682	0.00284	CbGeAlD
Zonisamide—SCN1B—Axon guidance—RHOB—systemic scleroderma	0.000677	0.0241	CbGpPWpGaD
Zonisamide—SCN2B—Axon guidance—RHOB—systemic scleroderma	0.000677	0.0241	CbGpPWpGaD
Zonisamide—SCN4B—Axon guidance—RHOB—systemic scleroderma	0.000619	0.0221	CbGpPWpGaD
Zonisamide—SCN3B—Axon guidance—RHOB—systemic scleroderma	0.000575	0.0205	CbGpPWpGaD
Zonisamide—SCN4B—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000564	0.0201	CbGpPWpGaD
Zonisamide—SCN3B—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000524	0.0187	CbGpPWpGaD
Zonisamide—CA1—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.000518	0.0185	CbGpPWpGaD
Zonisamide—SCN2B—Developmental Biology—RHOB—systemic scleroderma	0.000483	0.0172	CbGpPWpGaD
Zonisamide—SCN1B—Developmental Biology—RHOB—systemic scleroderma	0.000483	0.0172	CbGpPWpGaD
Zonisamide—SCN4B—Developmental Biology—RHOB—systemic scleroderma	0.000442	0.0158	CbGpPWpGaD
Zonisamide—SCN3B—Developmental Biology—RHOB—systemic scleroderma	0.000411	0.0147	CbGpPWpGaD
Zonisamide—MAOA—Serotonin Transporter Activity—IL1B—systemic scleroderma	0.000385	0.0137	CbGpPWpGaD
Zonisamide—SCN3B—Direct p53 effectors—MMP2—systemic scleroderma	0.000374	0.0133	CbGpPWpGaD
Zonisamide—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000351	0.000518	CcSEcCtD
Zonisamide—Fatigue—Mycophenolic acid—systemic scleroderma	0.00035	0.000517	CcSEcCtD
Zonisamide—Mood swings—Methotrexate—systemic scleroderma	0.00035	0.000517	CcSEcCtD
Zonisamide—Nausea—Mometasone—systemic scleroderma	0.000349	0.000516	CcSEcCtD
Zonisamide—Anorexia—Lisinopril—systemic scleroderma	0.000349	0.000515	CcSEcCtD
Zonisamide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000348	0.000514	CcSEcCtD
Zonisamide—Weight increased—Prednisone—systemic scleroderma	0.000348	0.000514	CcSEcCtD
Zonisamide—Ataxia—Methotrexate—systemic scleroderma	0.000347	0.000513	CcSEcCtD
Zonisamide—Constipation—Mycophenolic acid—systemic scleroderma	0.000347	0.000513	CcSEcCtD
Zonisamide—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000347	0.000513	CcSEcCtD
Zonisamide—Weight decreased—Prednisone—systemic scleroderma	0.000346	0.000511	CcSEcCtD
Zonisamide—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000345	0.00051	CcSEcCtD
Zonisamide—Cough—Mycophenolate mofetil—systemic scleroderma	0.000343	0.000506	CcSEcCtD
Zonisamide—Hypotension—Lisinopril—systemic scleroderma	0.000342	0.000505	CcSEcCtD
Zonisamide—MAOA—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000342	0.0122	CbGpPWpGaD
Zonisamide—Dizziness—Captopril—systemic scleroderma	0.000342	0.000505	CcSEcCtD
Zonisamide—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000341	0.000504	CcSEcCtD
Zonisamide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00034	0.000503	CcSEcCtD
Zonisamide—Depression—Prednisone—systemic scleroderma	0.00034	0.000502	CcSEcCtD
Zonisamide—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000339	0.000501	CcSEcCtD
Zonisamide—Urticaria—Leflunomide—systemic scleroderma	0.000338	0.0005	CcSEcCtD
Zonisamide—Body temperature increased—Leflunomide—systemic scleroderma	0.000337	0.000497	CcSEcCtD
Zonisamide—Abdominal pain—Leflunomide—systemic scleroderma	0.000337	0.000497	CcSEcCtD
Zonisamide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000335	0.000494	CcSEcCtD
Zonisamide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000334	0.000494	CcSEcCtD
Zonisamide—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000334	0.000494	CcSEcCtD
Zonisamide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000334	0.000494	CcSEcCtD
Zonisamide—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000334	0.000493	CcSEcCtD
Zonisamide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000333	0.000492	CcSEcCtD
Zonisamide—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000333	0.000492	CcSEcCtD
Zonisamide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000333	0.000491	CcSEcCtD
Zonisamide—Hypersensitivity—Azathioprine—systemic scleroderma	0.000332	0.000491	CcSEcCtD
Zonisamide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000332	0.000491	CcSEcCtD
Zonisamide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000332	0.00049	CcSEcCtD
Zonisamide—Insomnia—Lisinopril—systemic scleroderma	0.000331	0.000489	CcSEcCtD
Zonisamide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00033	0.000488	CcSEcCtD
Zonisamide—Paraesthesia—Lisinopril—systemic scleroderma	0.000329	0.000485	CcSEcCtD
Zonisamide—Vomiting—Captopril—systemic scleroderma	0.000329	0.000485	CcSEcCtD
Zonisamide—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000327	0.000483	CcSEcCtD
Zonisamide—Dyspnoea—Lisinopril—systemic scleroderma	0.000326	0.000482	CcSEcCtD
Zonisamide—Rash—Captopril—systemic scleroderma	0.000326	0.000481	CcSEcCtD
Zonisamide—Dermatitis—Captopril—systemic scleroderma	0.000325	0.000481	CcSEcCtD
Zonisamide—Somnolence—Lisinopril—systemic scleroderma	0.000325	0.00048	CcSEcCtD
Zonisamide—Headache—Captopril—systemic scleroderma	0.000324	0.000478	CcSEcCtD
Zonisamide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000323	0.000477	CcSEcCtD
Zonisamide—Dyspepsia—Lisinopril—systemic scleroderma	0.000322	0.000476	CcSEcCtD
Zonisamide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000321	0.000474	CcSEcCtD
Zonisamide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000321	0.000474	CcSEcCtD
Zonisamide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000321	0.000473	CcSEcCtD
Zonisamide—Infection—Mycophenolate mofetil—systemic scleroderma	0.000319	0.00047	CcSEcCtD
Zonisamide—Decreased appetite—Lisinopril—systemic scleroderma	0.000318	0.00047	CcSEcCtD
Zonisamide—Eosinophilia—Methotrexate—systemic scleroderma	0.000316	0.000467	CcSEcCtD
Zonisamide—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000316	0.000466	CcSEcCtD
Zonisamide—Fatigue—Lisinopril—systemic scleroderma	0.000315	0.000466	CcSEcCtD
Zonisamide—Shock—Mycophenolate mofetil—systemic scleroderma	0.000315	0.000466	CcSEcCtD
Zonisamide—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000314	0.000464	CcSEcCtD
Zonisamide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000314	0.000464	CcSEcCtD
Zonisamide—Hypersensitivity—Leflunomide—systemic scleroderma	0.000314	0.000463	CcSEcCtD
Zonisamide—Pancreatitis—Methotrexate—systemic scleroderma	0.000313	0.000462	CcSEcCtD
Zonisamide—Constipation—Lisinopril—systemic scleroderma	0.000313	0.000462	CcSEcCtD
Zonisamide—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000313	0.000462	CcSEcCtD
Zonisamide—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000311	0.00046	CcSEcCtD
Zonisamide—Bradycardia—Prednisone—systemic scleroderma	0.000311	0.00046	CcSEcCtD
Zonisamide—CACNA1I—Axon guidance—RHOB—systemic scleroderma	0.000311	0.0111	CbGpPWpGaD
Zonisamide—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00031	0.000458	CcSEcCtD
Zonisamide—Diarrhoea—Azathioprine—systemic scleroderma	0.000309	0.000456	CcSEcCtD
Zonisamide—Nausea—Captopril—systemic scleroderma	0.000307	0.000453	CcSEcCtD
Zonisamide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000306	0.000451	CcSEcCtD
Zonisamide—Asthenia—Leflunomide—systemic scleroderma	0.000306	0.000451	CcSEcCtD
Zonisamide—Hallucination—Prednisone—systemic scleroderma	0.000304	0.000449	CcSEcCtD
Zonisamide—Pancytopenia—Methotrexate—systemic scleroderma	0.000303	0.000448	CcSEcCtD
Zonisamide—Feeling abnormal—Lisinopril—systemic scleroderma	0.000302	0.000445	CcSEcCtD
Zonisamide—Pruritus—Leflunomide—systemic scleroderma	0.000301	0.000445	CcSEcCtD
Zonisamide—Connective tissue disorder—Prednisone—systemic scleroderma	0.000301	0.000444	CcSEcCtD
Zonisamide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.0003	0.000442	CcSEcCtD
Zonisamide—CA9—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000299	0.0107	CbGpPWpGaD
Zonisamide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000299	0.000442	CcSEcCtD
Zonisamide—Dysuria—Methotrexate—systemic scleroderma	0.000299	0.000441	CcSEcCtD
Zonisamide—Dizziness—Azathioprine—systemic scleroderma	0.000298	0.00044	CcSEcCtD
Zonisamide—SCN11A—Axon guidance—RHOB—systemic scleroderma	0.000294	0.0105	CbGpPWpGaD
Zonisamide—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000294	0.000434	CcSEcCtD
Zonisamide—SCN4B—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000294	0.0105	CbGpPWpGaD
Zonisamide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000292	0.000431	CcSEcCtD
Zonisamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.000291	0.00043	CcSEcCtD
Zonisamide—Diarrhoea—Leflunomide—systemic scleroderma	0.000291	0.00043	CcSEcCtD
Zonisamide—Urticaria—Lisinopril—systemic scleroderma	0.000291	0.000429	CcSEcCtD
Zonisamide—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00029	0.000428	CcSEcCtD
Zonisamide—Abdominal pain—Lisinopril—systemic scleroderma	0.000289	0.000427	CcSEcCtD
Zonisamide—Body temperature increased—Lisinopril—systemic scleroderma	0.000289	0.000427	CcSEcCtD
Zonisamide—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000288	0.000425	CcSEcCtD
Zonisamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.000287	0.000424	CcSEcCtD
Zonisamide—Vomiting—Azathioprine—systemic scleroderma	0.000287	0.000423	CcSEcCtD
Zonisamide—Pneumonia—Methotrexate—systemic scleroderma	0.000286	0.000423	CcSEcCtD
Zonisamide—Eye disorder—Prednisone—systemic scleroderma	0.000286	0.000422	CcSEcCtD
Zonisamide—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000286	0.000422	CcSEcCtD
Zonisamide—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000285	0.000421	CcSEcCtD
Zonisamide—Rash—Azathioprine—systemic scleroderma	0.000284	0.00042	CcSEcCtD
Zonisamide—Dermatitis—Azathioprine—systemic scleroderma	0.000284	0.000419	CcSEcCtD
Zonisamide—Depression—Methotrexate—systemic scleroderma	0.000284	0.000419	CcSEcCtD
Zonisamide—Headache—Azathioprine—systemic scleroderma	0.000283	0.000417	CcSEcCtD
Zonisamide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000282	0.000417	CcSEcCtD
Zonisamide—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000282	0.000417	CcSEcCtD
Zonisamide—Dizziness—Leflunomide—systemic scleroderma	0.000282	0.000416	CcSEcCtD
Zonisamide—Renal failure—Methotrexate—systemic scleroderma	0.00028	0.000413	CcSEcCtD
Zonisamide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000279	0.000412	CcSEcCtD
Zonisamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000278	0.00041	CcSEcCtD
Zonisamide—Stomatitis—Methotrexate—systemic scleroderma	0.000278	0.00041	CcSEcCtD
Zonisamide—Conjunctivitis—Methotrexate—systemic scleroderma	0.000277	0.000409	CcSEcCtD
Zonisamide—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000277	0.000409	CcSEcCtD
Zonisamide—Immune system disorder—Prednisone—systemic scleroderma	0.000276	0.000408	CcSEcCtD
Zonisamide—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000274	0.000405	CcSEcCtD
Zonisamide—SCN3B—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000273	0.00975	CbGpPWpGaD
Zonisamide—Sweating—Methotrexate—systemic scleroderma	0.000273	0.000403	CcSEcCtD
Zonisamide—Haematuria—Methotrexate—systemic scleroderma	0.000272	0.000401	CcSEcCtD
Zonisamide—Vomiting—Leflunomide—systemic scleroderma	0.000271	0.0004	CcSEcCtD
Zonisamide—Alopecia—Prednisone—systemic scleroderma	0.00027	0.000399	CcSEcCtD
Zonisamide—Hypersensitivity—Lisinopril—systemic scleroderma	0.00027	0.000398	CcSEcCtD
Zonisamide—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000269	0.000398	CcSEcCtD
Zonisamide—Dizziness—Mycophenolic acid—systemic scleroderma	0.000269	0.000397	CcSEcCtD
Zonisamide—Rash—Leflunomide—systemic scleroderma	0.000269	0.000396	CcSEcCtD
Zonisamide—Dermatitis—Leflunomide—systemic scleroderma	0.000268	0.000396	CcSEcCtD
Zonisamide—Mental disorder—Prednisone—systemic scleroderma	0.000268	0.000396	CcSEcCtD
Zonisamide—Nausea—Azathioprine—systemic scleroderma	0.000268	0.000396	CcSEcCtD
Zonisamide—Headache—Leflunomide—systemic scleroderma	0.000267	0.000394	CcSEcCtD
Zonisamide—Malnutrition—Prednisone—systemic scleroderma	0.000266	0.000393	CcSEcCtD
Zonisamide—Agranulocytosis—Methotrexate—systemic scleroderma	0.000266	0.000392	CcSEcCtD
Zonisamide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000264	0.00039	CcSEcCtD
Zonisamide—Asthenia—Lisinopril—systemic scleroderma	0.000263	0.000388	CcSEcCtD
Zonisamide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000262	0.000387	CcSEcCtD
Zonisamide—Pruritus—Lisinopril—systemic scleroderma	0.000259	0.000382	CcSEcCtD
Zonisamide—Vomiting—Mycophenolic acid—systemic scleroderma	0.000258	0.000381	CcSEcCtD
Zonisamide—Rash—Mycophenolic acid—systemic scleroderma	0.000256	0.000378	CcSEcCtD
Zonisamide—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000256	0.000378	CcSEcCtD
Zonisamide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000255	0.000376	CcSEcCtD
Zonisamide—Headache—Mycophenolic acid—systemic scleroderma	0.000255	0.000376	CcSEcCtD
Zonisamide—Pharyngitis—Methotrexate—systemic scleroderma	0.000254	0.000375	CcSEcCtD
Zonisamide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000253	0.000374	CcSEcCtD
Zonisamide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000253	0.000374	CcSEcCtD
Zonisamide—Nausea—Leflunomide—systemic scleroderma	0.000253	0.000374	CcSEcCtD
Zonisamide—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000252	0.000373	CcSEcCtD
Zonisamide—Urethral disorder—Methotrexate—systemic scleroderma	0.000251	0.00037	CcSEcCtD
Zonisamide—Diarrhoea—Lisinopril—systemic scleroderma	0.00025	0.00037	CcSEcCtD
Zonisamide—Ill-defined disorder—Prednisone—systemic scleroderma	0.000247	0.000365	CcSEcCtD
Zonisamide—Anaemia—Prednisone—systemic scleroderma	0.000246	0.000363	CcSEcCtD
Zonisamide—Agitation—Prednisone—systemic scleroderma	0.000245	0.000361	CcSEcCtD
Zonisamide—Dizziness—Lisinopril—systemic scleroderma	0.000242	0.000357	CcSEcCtD
Zonisamide—Erythema multiforme—Methotrexate—systemic scleroderma	0.000242	0.000357	CcSEcCtD
Zonisamide—Nausea—Mycophenolic acid—systemic scleroderma	0.000241	0.000356	CcSEcCtD
Zonisamide—Malaise—Prednisone—systemic scleroderma	0.00024	0.000355	CcSEcCtD
Zonisamide—Vertigo—Prednisone—systemic scleroderma	0.000239	0.000353	CcSEcCtD
Zonisamide—CA13—Metabolism—HSPG2—systemic scleroderma	0.000239	0.00853	CbGpPWpGaD
Zonisamide—Eye disorder—Methotrexate—systemic scleroderma	0.000239	0.000353	CcSEcCtD
Zonisamide—Syncope—Prednisone—systemic scleroderma	0.000239	0.000353	CcSEcCtD
Zonisamide—Tinnitus—Methotrexate—systemic scleroderma	0.000238	0.000352	CcSEcCtD
Zonisamide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000236	0.000349	CcSEcCtD
Zonisamide—Loss of consciousness—Prednisone—systemic scleroderma	0.000234	0.000346	CcSEcCtD
Zonisamide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	0.000233	0.00831	CbGpPWpGaD
Zonisamide—Vomiting—Lisinopril—systemic scleroderma	0.000233	0.000344	CcSEcCtD
Zonisamide—Immune system disorder—Methotrexate—systemic scleroderma	0.000231	0.000341	CcSEcCtD
Zonisamide—Rash—Lisinopril—systemic scleroderma	0.000231	0.000341	CcSEcCtD
Zonisamide—Convulsion—Prednisone—systemic scleroderma	0.000231	0.000341	CcSEcCtD
Zonisamide—Dermatitis—Lisinopril—systemic scleroderma	0.000231	0.00034	CcSEcCtD
Zonisamide—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00023	0.00034	CcSEcCtD
Zonisamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00023	0.00034	CcSEcCtD
Zonisamide—Hypertension—Prednisone—systemic scleroderma	0.00023	0.000339	CcSEcCtD
Zonisamide—Headache—Lisinopril—systemic scleroderma	0.000229	0.000339	CcSEcCtD
Zonisamide—CACNA1G—Axon guidance—RHOB—systemic scleroderma	0.000229	0.00817	CbGpPWpGaD
Zonisamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000227	0.000335	CcSEcCtD
Zonisamide—Myalgia—Prednisone—systemic scleroderma	0.000227	0.000335	CcSEcCtD
Zonisamide—Arthralgia—Prednisone—systemic scleroderma	0.000227	0.000335	CcSEcCtD
Zonisamide—Anxiety—Prednisone—systemic scleroderma	0.000226	0.000334	CcSEcCtD
Zonisamide—Alopecia—Methotrexate—systemic scleroderma	0.000226	0.000334	CcSEcCtD
Zonisamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000225	0.000332	CcSEcCtD
Zonisamide—SCN2B—Axon guidance—MMP2—systemic scleroderma	0.000225	0.00802	CbGpPWpGaD
Zonisamide—SCN1B—Axon guidance—MMP2—systemic scleroderma	0.000225	0.00802	CbGpPWpGaD
Zonisamide—Discomfort—Prednisone—systemic scleroderma	0.000224	0.000331	CcSEcCtD
Zonisamide—Mental disorder—Methotrexate—systemic scleroderma	0.000224	0.000331	CcSEcCtD
Zonisamide—Malnutrition—Methotrexate—systemic scleroderma	0.000223	0.000329	CcSEcCtD
Zonisamide—CACNA1H—Axon guidance—RHOB—systemic scleroderma	0.000222	0.00792	CbGpPWpGaD
Zonisamide—CACNA1I—Developmental Biology—RHOB—systemic scleroderma	0.000222	0.00791	CbGpPWpGaD
Zonisamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000219	0.000324	CcSEcCtD
Zonisamide—Dysgeusia—Methotrexate—systemic scleroderma	0.000218	0.000322	CcSEcCtD
Zonisamide—SCN9A—Axon guidance—RHOB—systemic scleroderma	0.000218	0.00777	CbGpPWpGaD
Zonisamide—Nausea—Lisinopril—systemic scleroderma	0.000217	0.000321	CcSEcCtD
Zonisamide—Oedema—Prednisone—systemic scleroderma	0.000217	0.000321	CcSEcCtD
Zonisamide—Infection—Prednisone—systemic scleroderma	0.000216	0.000319	CcSEcCtD
Zonisamide—Shock—Prednisone—systemic scleroderma	0.000214	0.000316	CcSEcCtD
Zonisamide—Nervous system disorder—Prednisone—systemic scleroderma	0.000213	0.000315	CcSEcCtD
Zonisamide—Tachycardia—Prednisone—systemic scleroderma	0.000212	0.000313	CcSEcCtD
Zonisamide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000212	0.000313	CcSEcCtD
Zonisamide—Skin disorder—Prednisone—systemic scleroderma	0.000211	0.000312	CcSEcCtD
Zonisamide—SCN11A—Developmental Biology—RHOB—systemic scleroderma	0.00021	0.0075	CbGpPWpGaD
Zonisamide—Hyperhidrosis—Prednisone—systemic scleroderma	0.00021	0.00031	CcSEcCtD
Zonisamide—SCN3A—Axon guidance—RHOB—systemic scleroderma	0.000208	0.00744	CbGpPWpGaD
Zonisamide—Anorexia—Prednisone—systemic scleroderma	0.000207	0.000306	CcSEcCtD
Zonisamide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000206	0.000305	CcSEcCtD
Zonisamide—Anaemia—Methotrexate—systemic scleroderma	0.000206	0.000304	CcSEcCtD
Zonisamide—SCN4B—Axon guidance—MMP2—systemic scleroderma	0.000205	0.00733	CbGpPWpGaD
Zonisamide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000204	0.000301	CcSEcCtD
Zonisamide—Rash—Mycophenolate mofetil—systemic scleroderma	0.000202	0.000299	CcSEcCtD
Zonisamide—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000202	0.000298	CcSEcCtD
Zonisamide—Headache—Mycophenolate mofetil—systemic scleroderma	0.000201	0.000297	CcSEcCtD
Zonisamide—Malaise—Methotrexate—systemic scleroderma	0.000201	0.000296	CcSEcCtD
Zonisamide—SCN4A—Axon guidance—RHOB—systemic scleroderma	0.0002	0.00714	CbGpPWpGaD
Zonisamide—SCN2A—Axon guidance—RHOB—systemic scleroderma	0.0002	0.00714	CbGpPWpGaD
Zonisamide—Vertigo—Methotrexate—systemic scleroderma	0.0002	0.000295	CcSEcCtD
Zonisamide—Leukopenia—Methotrexate—systemic scleroderma	0.000199	0.000294	CcSEcCtD
Zonisamide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000198	0.000292	CcSEcCtD
Zonisamide—Insomnia—Prednisone—systemic scleroderma	0.000197	0.00029	CcSEcCtD
Zonisamide—SCN5A—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000196	0.00701	CbGpPWpGaD
Zonisamide—Paraesthesia—Prednisone—systemic scleroderma	0.000195	0.000288	CcSEcCtD
Zonisamide—Cough—Methotrexate—systemic scleroderma	0.000194	0.000287	CcSEcCtD
Zonisamide—SCN1A—Axon guidance—RHOB—systemic scleroderma	0.000193	0.00689	CbGpPWpGaD
Zonisamide—Convulsion—Methotrexate—systemic scleroderma	0.000193	0.000285	CcSEcCtD
Zonisamide—Dyspepsia—Prednisone—systemic scleroderma	0.000191	0.000282	CcSEcCtD
Zonisamide—SCN3B—Axon guidance—MMP2—systemic scleroderma	0.000191	0.00682	CbGpPWpGaD
Zonisamide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00019	0.000281	CcSEcCtD
Zonisamide—Arthralgia—Methotrexate—systemic scleroderma	0.000189	0.00028	CcSEcCtD
Zonisamide—Chest pain—Methotrexate—systemic scleroderma	0.000189	0.00028	CcSEcCtD
Zonisamide—Myalgia—Methotrexate—systemic scleroderma	0.000189	0.00028	CcSEcCtD
Zonisamide—Decreased appetite—Prednisone—systemic scleroderma	0.000189	0.000279	CcSEcCtD
Zonisamide—CACNA1H—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000189	0.00674	CbGpPWpGaD
Zonisamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000188	0.000278	CcSEcCtD
Zonisamide—Fatigue—Prednisone—systemic scleroderma	0.000187	0.000277	CcSEcCtD
Zonisamide—Discomfort—Methotrexate—systemic scleroderma	0.000187	0.000276	CcSEcCtD
Zonisamide—Constipation—Prednisone—systemic scleroderma	0.000186	0.000274	CcSEcCtD
Zonisamide—Confusional state—Methotrexate—systemic scleroderma	0.000183	0.00027	CcSEcCtD
Zonisamide—CA13—Metabolism—CTGF—systemic scleroderma	0.000181	0.00646	CbGpPWpGaD
Zonisamide—Infection—Methotrexate—systemic scleroderma	0.00018	0.000266	CcSEcCtD
Zonisamide—Feeling abnormal—Prednisone—systemic scleroderma	0.000179	0.000264	CcSEcCtD
Zonisamide—Nervous system disorder—Methotrexate—systemic scleroderma	0.000178	0.000263	CcSEcCtD
Zonisamide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000178	0.000263	CcSEcCtD
Zonisamide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000178	0.000262	CcSEcCtD
Zonisamide—Skin disorder—Methotrexate—systemic scleroderma	0.000176	0.000261	CcSEcCtD
Zonisamide—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000176	0.000259	CcSEcCtD
Zonisamide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	0.000175	0.00625	CbGpPWpGaD
Zonisamide—Anorexia—Methotrexate—systemic scleroderma	0.000173	0.000256	CcSEcCtD
Zonisamide—Urticaria—Prednisone—systemic scleroderma	0.000173	0.000255	CcSEcCtD
Zonisamide—Abdominal pain—Prednisone—systemic scleroderma	0.000172	0.000254	CcSEcCtD
Zonisamide—Body temperature increased—Prednisone—systemic scleroderma	0.000172	0.000254	CcSEcCtD
Zonisamide—Hypotension—Methotrexate—systemic scleroderma	0.00017	0.000251	CcSEcCtD
Zonisamide—SCN2B—Axon guidance—MMP9—systemic scleroderma	0.000169	0.00603	CbGpPWpGaD
Zonisamide—SCN1B—Axon guidance—MMP9—systemic scleroderma	0.000169	0.00603	CbGpPWpGaD
Zonisamide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000165	0.000244	CcSEcCtD
Zonisamide—Insomnia—Methotrexate—systemic scleroderma	0.000164	0.000243	CcSEcCtD
Zonisamide—CACNA1G—Developmental Biology—RHOB—systemic scleroderma	0.000163	0.00583	CbGpPWpGaD
Zonisamide—Paraesthesia—Methotrexate—systemic scleroderma	0.000163	0.000241	CcSEcCtD
Zonisamide—Dyspnoea—Methotrexate—systemic scleroderma	0.000162	0.000239	CcSEcCtD
Zonisamide—CYP2C19—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000162	0.00577	CbGpPWpGaD
Zonisamide—Somnolence—Methotrexate—systemic scleroderma	0.000161	0.000238	CcSEcCtD
Zonisamide—SCN2B—Developmental Biology—MMP2—systemic scleroderma	0.00016	0.00572	CbGpPWpGaD
Zonisamide—SCN1B—Developmental Biology—MMP2—systemic scleroderma	0.00016	0.00572	CbGpPWpGaD
Zonisamide—Hypersensitivity—Prednisone—systemic scleroderma	0.00016	0.000236	CcSEcCtD
Zonisamide—Dyspepsia—Methotrexate—systemic scleroderma	0.00016	0.000236	CcSEcCtD
Zonisamide—CACNA1H—Developmental Biology—RHOB—systemic scleroderma	0.000158	0.00565	CbGpPWpGaD
Zonisamide—Decreased appetite—Methotrexate—systemic scleroderma	0.000158	0.000233	CcSEcCtD
Zonisamide—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000157	0.000232	CcSEcCtD
Zonisamide—Fatigue—Methotrexate—systemic scleroderma	0.000157	0.000231	CcSEcCtD
Zonisamide—Asthenia—Prednisone—systemic scleroderma	0.000156	0.00023	CcSEcCtD
Zonisamide—SCN9A—Developmental Biology—RHOB—systemic scleroderma	0.000155	0.00555	CbGpPWpGaD
Zonisamide—SCN4B—Axon guidance—MMP9—systemic scleroderma	0.000154	0.00551	CbGpPWpGaD
Zonisamide—Pruritus—Prednisone—systemic scleroderma	0.000154	0.000227	CcSEcCtD
Zonisamide—Feeling abnormal—Methotrexate—systemic scleroderma	0.00015	0.000221	CcSEcCtD
Zonisamide—Diarrhoea—Prednisone—systemic scleroderma	0.000149	0.00022	CcSEcCtD
Zonisamide—SCN3A—Developmental Biology—RHOB—systemic scleroderma	0.000149	0.00531	CbGpPWpGaD
Zonisamide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000149	0.000219	CcSEcCtD
Zonisamide—SCN4B—Developmental Biology—MMP2—systemic scleroderma	0.000147	0.00523	CbGpPWpGaD
Zonisamide—Urticaria—Methotrexate—systemic scleroderma	0.000144	0.000213	CcSEcCtD
Zonisamide—Dizziness—Prednisone—systemic scleroderma	0.000144	0.000212	CcSEcCtD
Zonisamide—SCN3B—Axon guidance—MMP9—systemic scleroderma	0.000144	0.00512	CbGpPWpGaD
Zonisamide—Body temperature increased—Methotrexate—systemic scleroderma	0.000144	0.000212	CcSEcCtD
Zonisamide—Abdominal pain—Methotrexate—systemic scleroderma	0.000144	0.000212	CcSEcCtD
Zonisamide—SCN2A—Developmental Biology—RHOB—systemic scleroderma	0.000143	0.0051	CbGpPWpGaD
Zonisamide—SCN4A—Developmental Biology—RHOB—systemic scleroderma	0.000143	0.0051	CbGpPWpGaD
Zonisamide—MAOA—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000141	0.00502	CbGpPWpGaD
Zonisamide—Vomiting—Prednisone—systemic scleroderma	0.000138	0.000204	CcSEcCtD
Zonisamide—SCN1A—Developmental Biology—RHOB—systemic scleroderma	0.000138	0.00492	CbGpPWpGaD
Zonisamide—Rash—Prednisone—systemic scleroderma	0.000137	0.000202	CcSEcCtD
Zonisamide—Dermatitis—Prednisone—systemic scleroderma	0.000137	0.000202	CcSEcCtD
Zonisamide—SCN3B—Developmental Biology—MMP2—systemic scleroderma	0.000136	0.00487	CbGpPWpGaD
Zonisamide—Headache—Prednisone—systemic scleroderma	0.000136	0.000201	CcSEcCtD
Zonisamide—SCN5A—Axon guidance—RHOB—systemic scleroderma	0.000136	0.00484	CbGpPWpGaD
Zonisamide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000134	0.000198	CcSEcCtD
Zonisamide—Asthenia—Methotrexate—systemic scleroderma	0.00013	0.000192	CcSEcCtD
Zonisamide—Nausea—Prednisone—systemic scleroderma	0.000129	0.000191	CcSEcCtD
Zonisamide—Pruritus—Methotrexate—systemic scleroderma	0.000129	0.00019	CcSEcCtD
Zonisamide—CA3—Metabolism—HSPG2—systemic scleroderma	0.000126	0.00448	CbGpPWpGaD
Zonisamide—CACNA1H—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000125	0.00446	CbGpPWpGaD
Zonisamide—Diarrhoea—Methotrexate—systemic scleroderma	0.000124	0.000184	CcSEcCtD
Zonisamide—SCN5A—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000124	0.00441	CbGpPWpGaD
Zonisamide—SCN1B—Developmental Biology—MMP9—systemic scleroderma	0.000121	0.0043	CbGpPWpGaD
Zonisamide—SCN2B—Developmental Biology—MMP9—systemic scleroderma	0.000121	0.0043	CbGpPWpGaD
Zonisamide—Dizziness—Methotrexate—systemic scleroderma	0.00012	0.000177	CcSEcCtD
Zonisamide—SCN5A—Cardiac Progenitor Differentiation—TGFB1—systemic scleroderma	0.000119	0.00424	CbGpPWpGaD
Zonisamide—Vomiting—Methotrexate—systemic scleroderma	0.000115	0.000171	CcSEcCtD
Zonisamide—Rash—Methotrexate—systemic scleroderma	0.000115	0.000169	CcSEcCtD
Zonisamide—Dermatitis—Methotrexate—systemic scleroderma	0.000114	0.000169	CcSEcCtD
Zonisamide—Headache—Methotrexate—systemic scleroderma	0.000114	0.000168	CcSEcCtD
Zonisamide—SCN4B—Developmental Biology—MMP9—systemic scleroderma	0.00011	0.00393	CbGpPWpGaD
Zonisamide—Nausea—Methotrexate—systemic scleroderma	0.000108	0.000159	CcSEcCtD
Zonisamide—CACNA1I—Axon guidance—MMP2—systemic scleroderma	0.000103	0.00368	CbGpPWpGaD
Zonisamide—SCN3B—Developmental Biology—MMP9—systemic scleroderma	0.000102	0.00366	CbGpPWpGaD
Zonisamide—SCN2B—Developmental Biology—TGFB1—systemic scleroderma	9.93e-05	0.00354	CbGpPWpGaD
Zonisamide—SCN1B—Developmental Biology—TGFB1—systemic scleroderma	9.93e-05	0.00354	CbGpPWpGaD
Zonisamide—CA9—Cellular responses to stress—IL1A—systemic scleroderma	9.81e-05	0.0035	CbGpPWpGaD
Zonisamide—SCN11A—Axon guidance—MMP2—systemic scleroderma	9.78e-05	0.00349	CbGpPWpGaD
Zonisamide—SCN5A—Developmental Biology—RHOB—systemic scleroderma	9.68e-05	0.00346	CbGpPWpGaD
Zonisamide—CA3—Metabolism—CTGF—systemic scleroderma	9.51e-05	0.0034	CbGpPWpGaD
Zonisamide—SCN4B—Developmental Biology—TGFB1—systemic scleroderma	9.08e-05	0.00324	CbGpPWpGaD
Zonisamide—MAOA—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	8.84e-05	0.00316	CbGpPWpGaD
Zonisamide—SCN3B—Developmental Biology—TGFB1—systemic scleroderma	8.44e-05	0.00301	CbGpPWpGaD
Zonisamide—CA14—Metabolism—HSPG2—systemic scleroderma	8.09e-05	0.00289	CbGpPWpGaD
Zonisamide—AOX1—Disease—SMAD7—systemic scleroderma	8.02e-05	0.00286	CbGpPWpGaD
Zonisamide—CA5A—Metabolism—HSPG2—systemic scleroderma	7.88e-05	0.00281	CbGpPWpGaD
Zonisamide—CA6—Metabolism—HSPG2—systemic scleroderma	7.88e-05	0.00281	CbGpPWpGaD
Zonisamide—CA13—Metabolism—NOS3—systemic scleroderma	7.88e-05	0.00281	CbGpPWpGaD
Zonisamide—CACNA1I—Axon guidance—MMP9—systemic scleroderma	7.75e-05	0.00277	CbGpPWpGaD
Zonisamide—CACNA1G—Axon guidance—MMP2—systemic scleroderma	7.61e-05	0.00271	CbGpPWpGaD
Zonisamide—CACNA1H—Axon guidance—MMP2—systemic scleroderma	7.37e-05	0.00263	CbGpPWpGaD
Zonisamide—CACNA1I—Developmental Biology—MMP2—systemic scleroderma	7.36e-05	0.00263	CbGpPWpGaD
Zonisamide—CA7—Metabolism—HSPG2—systemic scleroderma	7.36e-05	0.00263	CbGpPWpGaD
Zonisamide—CA5B—Metabolism—HSPG2—systemic scleroderma	7.36e-05	0.00263	CbGpPWpGaD
Zonisamide—SCN11A—Axon guidance—MMP9—systemic scleroderma	7.35e-05	0.00262	CbGpPWpGaD
Zonisamide—AOX1—Disease—TGFBI—systemic scleroderma	7.34e-05	0.00262	CbGpPWpGaD
Zonisamide—SCN9A—Axon guidance—MMP2—systemic scleroderma	7.23e-05	0.00258	CbGpPWpGaD
Zonisamide—SCN11A—Developmental Biology—MMP2—systemic scleroderma	6.98e-05	0.00249	CbGpPWpGaD
Zonisamide—SCN3A—Axon guidance—MMP2—systemic scleroderma	6.92e-05	0.00247	CbGpPWpGaD
Zonisamide—CA12—Metabolism—HSPG2—systemic scleroderma	6.82e-05	0.00243	CbGpPWpGaD
Zonisamide—SCN4A—Axon guidance—MMP2—systemic scleroderma	6.65e-05	0.00237	CbGpPWpGaD
Zonisamide—SCN2A—Axon guidance—MMP2—systemic scleroderma	6.65e-05	0.00237	CbGpPWpGaD
Zonisamide—SCN5A—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	6.45e-05	0.0023	CbGpPWpGaD
Zonisamide—SCN1A—Axon guidance—MMP2—systemic scleroderma	6.41e-05	0.00229	CbGpPWpGaD
Zonisamide—CA14—Metabolism—CTGF—systemic scleroderma	6.13e-05	0.00219	CbGpPWpGaD
Zonisamide—CA5A—Metabolism—CTGF—systemic scleroderma	5.97e-05	0.00213	CbGpPWpGaD
Zonisamide—CA6—Metabolism—CTGF—systemic scleroderma	5.97e-05	0.00213	CbGpPWpGaD
Zonisamide—AOX1—Disease—HSPG2—systemic scleroderma	5.85e-05	0.00209	CbGpPWpGaD
Zonisamide—CACNA1G—Axon guidance—MMP9—systemic scleroderma	5.72e-05	0.00204	CbGpPWpGaD
Zonisamide—AOX1—Disease—CSK—systemic scleroderma	5.65e-05	0.00202	CbGpPWpGaD
Zonisamide—CA7—Metabolism—CTGF—systemic scleroderma	5.58e-05	0.00199	CbGpPWpGaD
Zonisamide—CA5B—Metabolism—CTGF—systemic scleroderma	5.58e-05	0.00199	CbGpPWpGaD
Zonisamide—CACNA1H—Axon guidance—MMP9—systemic scleroderma	5.54e-05	0.00198	CbGpPWpGaD
Zonisamide—CACNA1I—Developmental Biology—MMP9—systemic scleroderma	5.53e-05	0.00197	CbGpPWpGaD
Zonisamide—SCN9A—Axon guidance—MMP9—systemic scleroderma	5.44e-05	0.00194	CbGpPWpGaD
Zonisamide—CA4—Metabolism—HSPG2—systemic scleroderma	5.44e-05	0.00194	CbGpPWpGaD
Zonisamide—CACNA1G—Developmental Biology—MMP2—systemic scleroderma	5.43e-05	0.00194	CbGpPWpGaD
Zonisamide—AOX1—Disease—CD247—systemic scleroderma	5.31e-05	0.0019	CbGpPWpGaD
Zonisamide—CACNA1H—Developmental Biology—MMP2—systemic scleroderma	5.26e-05	0.00188	CbGpPWpGaD
Zonisamide—SCN11A—Developmental Biology—MMP9—systemic scleroderma	5.25e-05	0.00187	CbGpPWpGaD
Zonisamide—CA2—Metabolism—HSPG2—systemic scleroderma	5.21e-05	0.00186	CbGpPWpGaD
Zonisamide—SCN3A—Axon guidance—MMP9—systemic scleroderma	5.2e-05	0.00186	CbGpPWpGaD
Zonisamide—CA12—Metabolism—CTGF—systemic scleroderma	5.17e-05	0.00184	CbGpPWpGaD
Zonisamide—SCN9A—Developmental Biology—MMP2—systemic scleroderma	5.16e-05	0.00184	CbGpPWpGaD
Zonisamide—CA1—Metabolism—HSPG2—systemic scleroderma	5e-05	0.00178	CbGpPWpGaD
Zonisamide—SCN4A—Axon guidance—MMP9—systemic scleroderma	5e-05	0.00178	CbGpPWpGaD
Zonisamide—SCN2A—Axon guidance—MMP9—systemic scleroderma	5e-05	0.00178	CbGpPWpGaD
Zonisamide—SCN3A—Developmental Biology—MMP2—systemic scleroderma	4.94e-05	0.00176	CbGpPWpGaD
Zonisamide—AOX1—Metabolism—HSPG2—systemic scleroderma	4.9e-05	0.00175	CbGpPWpGaD
Zonisamide—SCN1A—Axon guidance—MMP9—systemic scleroderma	4.82e-05	0.00172	CbGpPWpGaD
Zonisamide—SCN4A—Developmental Biology—MMP2—systemic scleroderma	4.74e-05	0.00169	CbGpPWpGaD
Zonisamide—SCN2A—Developmental Biology—MMP2—systemic scleroderma	4.74e-05	0.00169	CbGpPWpGaD
Zonisamide—MAOA—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	4.61e-05	0.00165	CbGpPWpGaD
Zonisamide—SCN1A—Developmental Biology—MMP2—systemic scleroderma	4.57e-05	0.00163	CbGpPWpGaD
Zonisamide—CACNA1I—Developmental Biology—TGFB1—systemic scleroderma	4.56e-05	0.00163	CbGpPWpGaD
Zonisamide—SCN5A—Axon guidance—MMP2—systemic scleroderma	4.51e-05	0.00161	CbGpPWpGaD
Zonisamide—CA9—Metabolism—HSPG2—systemic scleroderma	4.39e-05	0.00157	CbGpPWpGaD
Zonisamide—SCN11A—Developmental Biology—TGFB1—systemic scleroderma	4.32e-05	0.00154	CbGpPWpGaD
Zonisamide—MAOB—Metabolism—HSPG2—systemic scleroderma	4.14e-05	0.00148	CbGpPWpGaD
Zonisamide—CA3—Metabolism—NOS3—systemic scleroderma	4.14e-05	0.00148	CbGpPWpGaD
Zonisamide—CA4—Metabolism—CTGF—systemic scleroderma	4.12e-05	0.00147	CbGpPWpGaD
Zonisamide—CACNA1G—Developmental Biology—MMP9—systemic scleroderma	4.08e-05	0.00146	CbGpPWpGaD
Zonisamide—CACNA1H—Developmental Biology—MMP9—systemic scleroderma	3.95e-05	0.00141	CbGpPWpGaD
Zonisamide—CA2—Metabolism—CTGF—systemic scleroderma	3.95e-05	0.00141	CbGpPWpGaD
Zonisamide—SCN9A—Developmental Biology—MMP9—systemic scleroderma	3.88e-05	0.00138	CbGpPWpGaD
Zonisamide—CA1—Metabolism—CTGF—systemic scleroderma	3.79e-05	0.00135	CbGpPWpGaD
Zonisamide—AOX1—Metabolism—CTGF—systemic scleroderma	3.71e-05	0.00133	CbGpPWpGaD
Zonisamide—SCN3A—Developmental Biology—MMP9—systemic scleroderma	3.71e-05	0.00132	CbGpPWpGaD
Zonisamide—SCN2A—Developmental Biology—MMP9—systemic scleroderma	3.57e-05	0.00127	CbGpPWpGaD
Zonisamide—SCN4A—Developmental Biology—MMP9—systemic scleroderma	3.57e-05	0.00127	CbGpPWpGaD
Zonisamide—SCN1A—Developmental Biology—MMP9—systemic scleroderma	3.44e-05	0.00123	CbGpPWpGaD
Zonisamide—SCN5A—Axon guidance—MMP9—systemic scleroderma	3.39e-05	0.00121	CbGpPWpGaD
Zonisamide—CACNA1G—Developmental Biology—TGFB1—systemic scleroderma	3.36e-05	0.0012	CbGpPWpGaD
Zonisamide—CA9—Metabolism—CTGF—systemic scleroderma	3.33e-05	0.00119	CbGpPWpGaD
Zonisamide—CACNA1H—Developmental Biology—TGFB1—systemic scleroderma	3.26e-05	0.00116	CbGpPWpGaD
Zonisamide—SCN5A—Developmental Biology—MMP2—systemic scleroderma	3.22e-05	0.00115	CbGpPWpGaD
Zonisamide—SCN9A—Developmental Biology—TGFB1—systemic scleroderma	3.2e-05	0.00114	CbGpPWpGaD
Zonisamide—MAOB—Metabolism—CTGF—systemic scleroderma	3.14e-05	0.00112	CbGpPWpGaD
Zonisamide—SCN3A—Developmental Biology—TGFB1—systemic scleroderma	3.06e-05	0.00109	CbGpPWpGaD
Zonisamide—SCN2A—Developmental Biology—TGFB1—systemic scleroderma	2.94e-05	0.00105	CbGpPWpGaD
Zonisamide—SCN4A—Developmental Biology—TGFB1—systemic scleroderma	2.94e-05	0.00105	CbGpPWpGaD
Zonisamide—SCN1A—Developmental Biology—TGFB1—systemic scleroderma	2.83e-05	0.00101	CbGpPWpGaD
Zonisamide—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.76e-05	0.000986	CbGpPWpGaD
Zonisamide—CA14—Metabolism—NOS3—systemic scleroderma	2.67e-05	0.000952	CbGpPWpGaD
Zonisamide—CA6—Metabolism—NOS3—systemic scleroderma	2.6e-05	0.000928	CbGpPWpGaD
Zonisamide—CA5A—Metabolism—NOS3—systemic scleroderma	2.6e-05	0.000928	CbGpPWpGaD
Zonisamide—MAOA—Metabolism—HSPG2—systemic scleroderma	2.6e-05	0.000927	CbGpPWpGaD
Zonisamide—CA5B—Metabolism—NOS3—systemic scleroderma	2.43e-05	0.000866	CbGpPWpGaD
Zonisamide—CA7—Metabolism—NOS3—systemic scleroderma	2.43e-05	0.000866	CbGpPWpGaD
Zonisamide—SCN5A—Developmental Biology—MMP9—systemic scleroderma	2.42e-05	0.000863	CbGpPWpGaD
Zonisamide—CA12—Metabolism—NOS3—systemic scleroderma	2.25e-05	0.000803	CbGpPWpGaD
Zonisamide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.09e-05	0.000747	CbGpPWpGaD
Zonisamide—SCN5A—Developmental Biology—TGFB1—systemic scleroderma	1.99e-05	0.000711	CbGpPWpGaD
Zonisamide—MAOA—Metabolism—CTGF—systemic scleroderma	1.97e-05	0.000703	CbGpPWpGaD
Zonisamide—AOX1—Disease—NOS3—systemic scleroderma	1.93e-05	0.000689	CbGpPWpGaD
Zonisamide—CA4—Metabolism—NOS3—systemic scleroderma	1.79e-05	0.00064	CbGpPWpGaD
Zonisamide—CA2—Metabolism—NOS3—systemic scleroderma	1.72e-05	0.000614	CbGpPWpGaD
Zonisamide—CA1—Metabolism—NOS3—systemic scleroderma	1.65e-05	0.000588	CbGpPWpGaD
Zonisamide—AOX1—Metabolism—NOS3—systemic scleroderma	1.62e-05	0.000577	CbGpPWpGaD
Zonisamide—CA9—Metabolism—NOS3—systemic scleroderma	1.45e-05	0.000517	CbGpPWpGaD
Zonisamide—MAOB—Metabolism—NOS3—systemic scleroderma	1.37e-05	0.000488	CbGpPWpGaD
Zonisamide—AOX1—Disease—TGFB1—systemic scleroderma	1.28e-05	0.000456	CbGpPWpGaD
Zonisamide—CYP2C19—Metabolism—HSPG2—systemic scleroderma	1.23e-05	0.000439	CbGpPWpGaD
Zonisamide—CYP2C19—Metabolism—CTGF—systemic scleroderma	9.32e-06	0.000333	CbGpPWpGaD
Zonisamide—MAOA—Metabolism—NOS3—systemic scleroderma	8.57e-06	0.000306	CbGpPWpGaD
Zonisamide—CYP3A4—Metabolism—HSPG2—systemic scleroderma	7.4e-06	0.000264	CbGpPWpGaD
Zonisamide—CYP3A4—Metabolism—CTGF—systemic scleroderma	5.6e-06	0.0002	CbGpPWpGaD
Zonisamide—CYP2C19—Metabolism—NOS3—systemic scleroderma	4.06e-06	0.000145	CbGpPWpGaD
Zonisamide—CYP3A4—Metabolism—NOS3—systemic scleroderma	2.44e-06	8.71e-05	CbGpPWpGaD
